Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Evidence conditionIs the epinephrine-induced ex vivo platelet aggregation linked as a separate question and distinguished from the original broad verdict?Required	The original wording is reduced ex vivo platelet aggregation, and subclaims is an empty array. This table covers only the epinephrine-induced ex vivo platelet aggregation. C, 46 points and all axes are historical values of the broad parent. S01 S02 S03	For this narrow record-boundary criterion, the original claim, empty array, agonist distinction and formal derived assignment are linked. This does not establish clinical efficacy.	A record linking the original verdict claim, empty subclaims, derived question and parent verdict	If the boundary changes, redefine the agonist, measure and comparison as a new question and preserve the previous version.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre S01's actual AGE formulation and SAC specification verified for the epinephrine comparison?Required	The original claim conditions describe AGE capsules and unverified trial-specific SAC specifications. Raw garlic, garlic powder, oil, allicin, black garlic, fermented garlic and isolated SAC are not interchangeable. S01	The nominal AGE capsule formulation is recorded, but actual product, batch and SAC specifications remain to be verified.	Original product name, aging process, capsule content, batch SAC specification and actual administration data	In controlled studies with matching products and batches, link the administered substance and ingredient specifications to the analysis cell.
3	Unverified	Full text not readStored summary read	N03 · Evidence conditionIs the 1995 garlic preparation the same formulation as the AGE exposure in this epinephrine question?Required	S02's title refers to a garlic preparation and a small sample of healthy men. The retained summary does not specify whether the preparation was aged, its product or specifications. The 1995 report's endpoints are ADP, PAF and collagen. The current retained summary contains no epinephrine result, so its null result is not assigned as direct counterevidence for epinephrine. S02	S02 supplies related context, but original material confirming the same exposure as AGE is absent.	Actual ingredients, processing, product and specifications of the 1995 preparation and a mapping to S01 AGE	After checking formulation identity, compare whether the epinephrine measure matches; retain a separate preparation question if identity differs.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionAre the baseline status, eligibility and demographics of the actual epinephrine analysis population verified?Required	The claim conditions mainly concern healthy adults and treat antiplatelet co-use separately. S01 is summarized only as 34 people, without arm-specific demographics or baseline characteristics. S02's healthy-male information is not inherited by S01. S01 S02	The original scope mainly concerns healthy adults, but S01's actual selection and arm-specific baseline data remain unverified.	S01 arm-specific age, sex, baseline platelet function, eligibility/exclusions and medication-use tables	In studies reporting baseline characteristics, compare selection and arm balance alongside the epinephrine results.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionAre the nominal dose list and the actual dose and intake for the epinephrine result linked?Required	The original dose list is 2.4, 4.8 and 7.2 g/day. Although the trial doses are 2.4, 4.8 and 7.2 g/day, no material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine. S01	The dose list and a narrative clue for the selected response exist, but actual intake and result-cell mapping remain unverified.	Arm-specific planned doses, actual intake, adherence data and dose mapping for the epinephrine result cell	After obtaining dose-specific comparison tables, analyze planned epinephrine dose comparisons separately from actual intake.
6	Unverified	Full text not readStored summary read	N06 · Evidence conditionAre exposure duration and the interval from the last dose to epinephrine blood collection and testing verified?Required	The claim conditions describe only short-term exposure with durations differing across trials. S01's actual duration, blood-draw timing and interval from the last dose are absent. S01	The short-term description alone cannot establish the required actual timeline.	S01 start/end dates, actual weeks of exposure, last-dose/blood-draw interval and testing time	In comparisons with a defined timeline, record pre/post exposure and last-dose intervals under the same conditions.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionAre the placebo's actual composition and common management verified for the epinephrine comparison?Required	The claim conditions name placebo as comparator, and S01 is described as a placebo dose-ranging trial. Actual placebo composition, diet and arm-specific common management data are absent. S01	Nominal placebo control is identified, but actual composition, schedule and common management remain to be verified.	Placebo composition, dosing schedule, diet/management and arm differences	In placebo comparisons with matching management, examine arm-specific management changes in relation to epinephrine results.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionAre the actual randomization, blinding and design procedures verified?Required	S01 is described as a randomized, double-blind, placebo-controlled dose-ranging trial. Actual sequence generation/concealment, parallel/crossover structure and blinding assessment data are absent. S01	The summary classifies the design, but actual conduct has not been verified.	Methods for sequence generation/concealment, parallel/crossover structure, blinding maintenance and baseline balance	After comparing methods, assess allocation and specimen evaluation blinding according to the actual design.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionCan information on concomitant drugs, diet, adherence and exposure deviations affecting the epinephrine difference be verified?Required	The original population scope treats antiplatelet co-use separately and gives safety warnings. S01's actual co-medication, adherence, rescue/discontinuation data remain unverified. S01	Background-risk warnings exist but do not replace actual arm-specific exposure records.	Arm-specific anticoagulants/antiplatelets, diet, rescue treatment, adherence/discontinuation and analysis handling	In comparisons recording actual co-medication and deviations, review them according to the effect of interest and analysis handling.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionAre the exact measure, unit and direction of the epinephrine result verified?Required	S01's selected clue is a partial reduction in epinephrine-induced aggregation. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the corresponding analysis cell remain unverified. The representative endpoint in the claim conditions broadly includes maximum aggregation or threshold. S01	A directional or threshold clue exists, but the unit, definition and original analysis cell remain to be verified.	Original epinephrine result tables, threshold/maximum-aggregation definitions, units and positive cells	Fix the epinephrine measure and unit from the original result table before comparing between-arm results on the same measure.
11	Unverified	Full text not readStored summary read	N11 · Evidence conditionAre epinephrine concentration, specimen processing, equipment and repeated-specimen structure verified?Required	The original material summarizes agonist-specific ex vivo aggregation but does not give epinephrine concentration, specimen processing, equipment or specimen repeat counts. S01	Without actual analysis conditions, effects of concentration or assay method cannot be compared.	Agonist concentration, PRP/specimen processing, equipment, measurement time and repeat/specimen identifiers	Specify matching concentration, specimen processing and assay methods, and design comparisons accounting for within-person repeats.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionWhich between-arm contrast and analysis population does the selected epinephrine value estimate?Required	S01's result is a directional summary of a partial reduction in epinephrine-induced aggregation. Whether it is a within-arm change or a placebo comparison, end value/change, ITT/PP or adjusted/unadjusted model is unverified in the current material. S01	The directional summary lacks the required formal contrast and analysis definition. Valid unadjusted comparisons are allowed; adjustment is not universally required.	Baseline change/end values, between/within-arm comparisons, ITT/PP, models and dose/concentration-specific repeat handling	Compare the original analysis or an appropriate comparison model specifying the between-arm contrast; retain within-arm change separately.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionCan the original 34 people be distinguished from dose-specific epinephrine allocation, measurement and analysis denominators?Required	S01 reports n as 34 people. Whether this is recruitment, allocation, completion or analysis and each arm's epinephrine analysis count remain unverified. Three tables share the same 34-person trial. S01	The reported 34 people are identified, but actual dose/endpoint denominators are absent. They were not filled by division or addition.	Flow of total recruitment/allocation, dose/control-specific measured/analyzed people and specimen counts	Compare person/specimen identifier flow and state the analysis unit and arm-specific denominators.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionAre missingness, losses, failed measurements and their handling verified for the epinephrine analysis?Required	Beyond 34 people, the current evidence table has no actual loss, specimen-failure or analysis-exclusion counts or handling. Generic English sample-size wording is not actual denominator data. S01	Loss/missingness data are absent, so handling cannot be verified; losses were not filled as 0.	Dose-arm loss reasons, specimen/result missingness, analysis exclusions, imputation/sensitivity analyses	Review how missingness affects the contrast of interest using original data recording the types of omission.
15	Unverified	Full text not readStored summary read	N15 · Evidence conditionAre the formal epinephrine effect estimate, variance, P value and confidence interval verified?Required	The selected direction is a partial reduction in epinephrine-induced aggregation, but actual arm values, SD/SE, P and CI are absent from current evidence/citation summaries. No new difference, variance or interval is calculated. S01	Numerical data needed for the estimate and precision are absent, so verification is not possible.	Dose/concentration/time-specific arm values, SD/SE, between-arm estimate, P/CI and denominators	Obtain original estimates and intervals on the same epinephrine measure to compare magnitude and uncertainty.
16	Unverified	Full text not readStored summary read	N16 · Evidence conditionDo the registered/protocol/SAP prespecified epinephrine endpoint and report agree?Required	S01's registration field says not verified. Original plans, registration number, SAP and time-specific prespecified epinephrine definitions are absent. Non-acquisition does not establish non-registration or selective reporting. S01	Without prior planning material, adherence to the actual plan cannot be checked.	S01 actual registration identifier, protocol, SAP, dates/versions and analysis hierarchy	Compare dated plans and result tables to distinguish prespecified from post hoc analyses of the selected response.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionAre the testing scope and adjustment for multiple doses, agonists, concentrations/time points verified?Required	The manuscript notes multiple doses and agonists in the positive trial; S01's evidence weight notes multiplicity and a small sample. Actual test counts, concentration/time lists and adjustment status are absent. S01	Multiplicity is identified as a limitation, but the actual hierarchy, testing family and handling remain unverified.	Testing family, prespecified primary/secondary endpoints, all analysis tables and multiplicity handling	Examine multiple contrasts and selective reporting in plan-based analyses disclosing all results.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionCan the reported epinephrine direction be verified down to the actual measure and dose cell?Required	S01 and S01's citation summary indicate a partial reduction in epinephrine-induced aggregation. Although the trial doses are 2.4, 4.8 and 7.2 g/day, no material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the corresponding analysis cell remain unverified. S01	The direction is retained, but numerical results and conditions for all cells have not been verified.	All favorable/no-difference/unfavorable cells of the selected response and exact analysis locations	Compare all prespecified epinephrine dose/concentration cells, including cells without favorable results.
19	Met	Full text not readStored summary read	N19 · Evidence conditionHas S02's current null result been kept separate from direct epinephrine results?Required	S02 lists ADP, PAF and collagen aggregation and describes no significant oral effect. The current summary contains no epinephrine result. Its formulation has also not been confirmed as identical to AGE. S02	This row asks about the attribution scope of the current report. The other listed responses were distinguished from epinephrine.	S02's actual endpoint list and records of whether a selected epinephrine result exists	If new original material contains an epinephrine analysis, compare its formulation, measure and actual result separately.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionAre the AGE/epinephrine original trials and results in the 2022 review verified?Required	S03 summarizes 12 RCTs and 595 people, with 6 positive and the rest null; heterogeneity prevents a firm conclusion. Individual formulations, agonists and inclusion of S01/S02 are absent from the retained material. S03	The review's overall scope and directional heterogeneity are recorded, but the trial list matching this response remains unverified.	Review included-trial table and mapping of formulation, agonist, dose, population and endpoint to original results	Compare included trials with original reports, separate formulation/response-specific results and identify participant overlap.
21	Unverified	Full text not readStored summary read	N21 · Evidence conditionAre independent replication and unique participant counts for the same epinephrine/AGE question verified?Required	S01 is a shared 34-person trial. S02's AGE identity and S03's included-trial relationships remain unverified. The 34 and 595 people are not added, and three tables are not counted as three independent trials. S01 S02 S03	Material establishing matching replication and unique participant counts is absent.	Report/original-trial/cohort, included-trial overlap and response-specific analysis mapping	After checking actual study families and included-trial overlap, examine replication of the same epinephrine question.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionAre important-difference and interpretation criteria justified for this epinephrine measure?Required	The selected manuscript response is a partial reduction in epinephrine-induced aggregation, without important-difference criteria, assay reproducibility or CI data. No arbitrary MCID, minimum n or required weeks are created. S01	Without importance criteria and precision data, adequacy cannot be verified.	Measure-specific prespecified important difference, assay reproducibility/variation, rationale and original intervals	Specify reproducibility and a justified important difference for the measure, then compare them with formal estimates and intervals.
23	Met	Full text not readStored summary read	N23 · Evidence conditionIs the boundary between the selected ex vivo epinephrine response and clinical thrombosis/bleeding events distinguished?Supplementary; required for clinical-event extensions	The original explanation states that clinical thrombosis and bleeding were not measured, and its advertising guidance excludes thrombosis prevention, thrombolysis, aspirin replacement and bleeding-safety claims. Only the selected epinephrine experimental response is covered. S01 S02 S03	This item asks about the established endpoint boundary. Experimental response and clinical events are separated; clinical efficacy is not established.	A record linking the experimental endpoint to the scope of clinical-event/alternative-treatment claims	If clinical events are the question, examine them in separate comparisons with suitable populations, follow-up and event collection.
24	Met	Full text not readStored summary read	N24 · Evidence conditionIs the current scope of PAF, arachidonic acid and other responses distinguished from the epinephrine result?Required	The original crux distinguishes ADP, collagen, epinephrine and arachidonic acid. S02 includes PAF, but its AGE identity is unverified. Direct AA results are not linked in the 3 evidence/3 citation entries. These gaps remain in related PAF/arachidonic acid questions and the parent context. S01 S02 S03	This item asks about distinguishing the current reporting scope. Adjacent responses and result gaps are retained without adding them to the selected epinephrine estimate.	Current agonist-specific report lists, unverified PAF formulation identity and the AA result gap	When new original material for each response appears, define formulation, measure, concentration and comparator separately and examine it in a separate table version.
25	Unverified	Full text not readStored summary read	N25 · Evidence conditionIs there direct material on optimal dose, long-term persistence and epinephrine response after discontinuation?Supplementary; required for dose/persistence extensions	The original exposure is short-term and varies by trial; only a partial reduction in epinephrine-induced aggregation is retained. Direct long-term, post-withdrawal and optimal-dose material is absent. S01	The original dose-ranging direction and short-term material cannot answer extension questions.	Prespecified between-dose comparisons, exposure/withdrawal follow-up, long-term epinephrine results and interactions	If persistence or dose optimization is the objective, design separate prespecified dose comparisons and withdrawal/long-term follow-up.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionAre actual bleeding, adverse-event and discontinuation collection data verified for the same AGE exposure?Supplementary; required for harm interpretation	The original safety category is Warning, concerning unsupervised use with anticoagulants, antiplatelets, bleeding disorders and around surgery. Actual bleeding-event counts, collection, discontinuations and denominators are absent from the evidence table. S01 S02 S03	The warning scope is identified, but actual event-collection and harm-estimate data remain unverified.	Event definitions, active/spontaneous collection, timing, exposure/denominators, severity and discontinuation tables	For harm questions, examine separate material with event definitions, collection systems and appropriate follow-up.
27	Unverified	Full text not readStored summary read	N27 · Evidence conditionIs direct harm information verified for anticoagulant/antiplatelet co-use, bleeding disorders and surgical populations?Supplementary; required for vulnerable-group safety extensions	The manuscript warns these groups and treats antiplatelet co-use separately. Actual harm comparisons, denominators and long-term follow-up for each group are absent from the retained evidence table. S01 S02 S03	The caution scope exists, but direct vulnerable-group material is absent, so harm magnitude or safety cannot be verified.	Exposure, baseline risk, duration, harm events and comparison material in vulnerable/co-medication groups	For co-medication/vulnerable-group questions, use suitable separate comparison/follow-up designs recording baseline risk and actual exposure.
28	Unverified	Full text not readStored summary read	N28 · Evidence conditionAre actual funding, product support and employment/COI disclosures verified for the epinephrine material?Supplementary; required for independence claims	S01 records unverified product-support details, S02 unverified funding, and S03 academic research with mixed original-trial funding. Actual employment, product provision, COI wording and original-trial funding are absent. S01 S02 S03	Unverified support details cannot establish independence or absence of conflicts.	Original S01/S02 funding, product support, author employment/patents/COI and S03 included-trial material	Compare original disclosures and interpret results separately from study families and product support.
29	Met	Full text not readStored summary read	N29 · Evidence conditionAre study-family and review-recitation relationships for the three reports and shared epinephrine results stated?Required	S01 PMID 11238801 is one multi-dose/response trial. S02 PMID 8582091 reports another garlic preparation; S03 PMID 36222178 is a 12-RCT review. Actual review inclusion remains unverified. S01 S02 S03	This item asks for an honest verified/unverified distinction in family attribution records. Direct independent replication counts remain unverified in the separate unique-replication criterion.	Verified/unverified relationships among 3 reports, PMID/DOI, shared trials and review inclusion	Compare original trial identifiers with included-trial tables and update links when new overlap relationships are found.
30	Met	Full text not readStored summary read	N30 · Evidence conditionAre the original broad C46, all axes and the English-placeholder correction event preserved?Required	Original C, 46 points, B/S/R0/I1/EX/B2/CX and empty subclaims/deliberation are preserved. The original verdict-review date is 2026-09-08 and the correction event is 2026-09-14. The correction describes replacing English placeholders, but some current evidence English remains generic verification wording. These strings are also retained and are not used as actual n/P/CI. S01 S02 S03	This item asks about preserving original values and the correction event. Complete original material and types are retained without creating effects, grades or English clinical values.	The complete original record, both languages, axes, empty arrays/strings and original correction location/date	For future corrections, separate the before-text, event, new version and reason, then compare related observations/conditions.
31	Met	Full text not readStored summary read	N31 · Evidence conditionAre the original review date, correction date and current review scope distinguished?Required	The original review date is 2026-09-08 and the correction date is 2026-09-14. Original search-cut-off and report-specific access-date/reading-scope fields are absent. This review date is 2026-10-05; all current inputs were read without new external searches or full-text reading. S01 S02 S03	This item asks about date/scope labeling. Different events are distinguished and absent individual access dates remain unrecorded.	Original verdict-review date, correction event, currently read inputs and records of absent cut-off/access fields	If new material is permitted, add search/access/review dates and actual locations as separate events.
32	Met	Full text not readStored summary read	N32 · Evidence conditionAre current local-summary reading and unread external gateways/full texts distinguished by material?Required	The complete current retained source, Korean/English, 3 evidence entries, 3 citations and 1 correction were read locally. Access, acquisition and reading of PubMed gateways, DOI links and original-paper full texts were not attempted. Report-specific historical reading-scope/date fields are absent. S01 S02 S03	This item asks about actual current-action records. Local summaries and unread external material are separated; fields lacking original server metadata remain unrecorded.	Exact input locations/identity and actual actions for PubMed, DOI and full-text materials	For permitted new reading, separately record material type, version, success/failure, sections read, original location and identity.
33	Met	Full text not readStored summary read	N33 · Evidence conditionIs the remaining scope of external original-table, method and registration comparison stated?Required	Selected epinephrine values, specimen conditions, denominators and original-plan comparisons remain unverified in the retained material. Local item-specific condition/observation review was completed, but no new comparison with external original tables, methods or registration was performed. S01 S02 S03	This item evaluates only the statement of remaining comparison scope. Retained locations and unperformed external comparisons are distinguished; actual material requirements in preceding items remain unverified.	epinephrine original result tables, methods/appendices, actual registration/SAP identity and currently uncompared locations	If new external comparison is authorized, distinguish material acquisition from analysis methods and update each item according to actual results.

No items match your search or filter.

33 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence review date: 2026-09-08
Scope actually checked: Retained Korean/English summaries and case-specific condition/application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
Population: The scope mainly concerns healthy adults. S01 records a total sample of 34 people, but actual eligibility, baseline characteristics, sex, age and arm-specific analysis denominators remain unverified. S02’s healthy-male information is not transferred to S01.
Ingredient, formulation and route: Oral AGE capsules from aged Allium sativum L. clove extract. Product, manufacture/batch, aging process, SAC specification and actual administered material remain unverified. Other garlic preparations are not interchangeable.
Dose: The nominal dose list is 2.4, 4.8 and 7.2 g/day. No material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine.
Comparator: The selected epinephrine response compares oral AGE with placebo. Actual placebo composition, common management, between-arm contrast, analysis population and parallel/crossover structure remain unverified.
Measured outcome: The endpoint is epinephrine-induced ex vivo platelet aggregation. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the analysis cell remain unverified. Units, concentration, specimen processing, formal estimates and P/CI are also unverified.
Duration: Only a short-term scope with durations differing across trials is recorded. S01’s exact duration and interval from last dose to blood draw/testing remain unverified.
Questions outside this scope: Original C, 46 points, Warning and assessment axes are historical values of the broad parent verdict. No separate grade, score or effect is created for the selected epinephrine question.; S01’s 34 people are not divided into dose-arm, specimen or response-specific analysis counts or added as independent people across three tables of the same trial.; S02’s 1995 report lists ADP, PAF and collagen aggregation. Its retained summary contains no epinephrine result, and AGE identity remains unverified. It is not transferred as direct epinephrine counterevidence, an effect of 0 or equivalence.; The S03 review’s 12 RCTs, 595 people and 6 positive trials describe its overall summary. Selected AGE/epinephrine trials and inclusion/overlap of S01/S02 remain unverified; the review is not added as new independent trials or people.; The specimen epinephrine response does not establish thrombosis prevention, thrombolysis, aspirin replacement or bleeding safety. Long-term persistence, optimal dose, harms and vulnerable groups are extension questions requiring separate direct material.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Steiner M, Li W. J Nutr. 2001;131:980S-984S. PMID: 11238801. DOI: 10.1093/jn/131.3.980S.

PubMed

Material type: A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Findings recorded in the stored summary: The retained S01 summary describes a randomized, double-blind, placebo-controlled dose-ranging trial in 34 people. The nominal dose list is 2.4, 4.8 and 7.2 g/day, with only short-term exposure varying across trials retained; the exact S01 duration is unverified. The selected clue is a partial reduction in epinephrine-induced aggregation. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the analysis cell remain unverified. Although the trial doses are 2.4, 4.8 and 7.2 g/day, no material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine. Actual arm-specific epinephrine n, values, P/CI, concentration, variance and plans/analyses remain unverified. Product-support details and NCT are retained as unverified.
Record level: Direction and scope from the retained summary. The formal selected epinephrine estimate, CI, denominator and original result cell remain unverified.
Study overlap and independent replication: S01 contains multiple doses and responses from the same 34-person trial. S02 reports another preparation with unverified AGE identity; S03 is a review. Actual review inclusion, overlap with S01/S02 and unique direct trial/participant counts for the selected epinephrine response remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained verdict summary	Retained verdict summary read	Retained copy acquired; summary read	Stored existing review summary read	Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External PubMed bibliographic/abstract gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External DOI/publisher gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
Original paper full text; direct location/version unverified	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.

S02 · 1995 clinical trial. PMID: 8582091. DOI: 10.1111/j.1440-1681.1995.tb02032.x.

PubMed

Material type: A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Findings recorded in the stored summary: The retained S02 summary describes a small sample of healthy men in a double-blind placebo trial. The actual preparation is identified only as a garlic preparation; AGE identity, exact n, duration, dose and variance/CI remain unverified. Endpoints are ADP, PAF and collagen; the result is no significant in vivo oral effect. The 1995 report’s endpoints are ADP, PAF and collagen. The current retained summary contains no epinephrine result, so its null result is not assigned as direct counterevidence for epinephrine. Funding and registration remain unverified.
Record level: Direction and scope from the retained summary. The formal selected epinephrine estimate, CI, denominator and original result cell remain unverified.
Study overlap and independent replication: S01 contains multiple doses and responses from the same 34-person trial. S02 reports another preparation with unverified AGE identity; S03 is a review. Actual review inclusion, overlap with S01/S02 and unique direct trial/participant counts for the selected epinephrine response remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained verdict summary	Retained verdict summary read	Retained copy acquired; summary read	Stored existing review summary read	Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External PubMed bibliographic/abstract gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External DOI/publisher gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
Original paper full text; direct location/version unverified	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.

S03 · 2022 systematic review. PMID: 36222178. DOI: 10.1002/ptr.7556.

PubMed

Material type: A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Findings recorded in the stored summary: The retained S03 summary describes a systematic review of 12 RCTs and 595 people, with 6 positive and the rest null; heterogeneity prevents a firm conclusion. It is described as academic research with mixed original-trial funding. Original trials/unique denominators for the selected AGE/epinephrine question and inclusion of S01/S02 remain unverified. The review is not added as a new trial or newly recruited participants.
Record level: Direction and scope from the retained summary. The formal selected epinephrine estimate, CI, denominator and original result cell remain unverified.
Study overlap and independent replication: S01 contains multiple doses and responses from the same 34-person trial. S02 reports another preparation with unverified AGE identity; S03 is a review. Actual review inclusion, overlap with S01/S02 and unique direct trial/participant counts for the selected epinephrine response remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained verdict summary	Retained verdict summary read	Retained copy acquired; summary read	Stored existing review summary read	Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External PubMed bibliographic/abstract gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
External DOI/publisher gateway	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.
Original paper full text; direct location/version unverified	External access not attempted; not acquired; unread	External access not attempted; not acquired	Not read	The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion.

Report counts versus independent study counts

S01 contains multiple doses and responses from the same 34-person trial. S02 reports another preparation with unverified AGE identity; S03 is a review. Actual review inclusion, overlap with S01/S02 and unique direct trial/participant counts for the selected epinephrine response remain unverified.

Review criteria

Version 1.1 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Is the epinephrine-induced ex vivo platelet aggregation linked as a separate question and distinguished from the original broad verdict?

Required materials and conditions: A record linking the original verdict claim, empty subclaims, derived question and parent verdict
Conditions for verification: Retain the original wording, identify the epinephrine-induced ex vivo platelet aggregation as a separate target, and state that the derived ID is not an original array index.
Requirement and applicability: Required
Application exceptions: Only this item evaluates the recorded boundary. Other items requiring actual dose, denominator and estimate material are assessed separately.
Why this condition is needed: This prevents biologically different agonist responses from being combined into one estimate or a new grade.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N02 · Are S01's actual AGE formulation and SAC specification verified for the epinephrine comparison?

Required materials and conditions: Original product name, aging process, capsule content, batch SAC specification and actual administration data
Conditions for verification: Link the actual AGE capsule product and ingredient specifications to the exposure used for epinephrine analysis.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: Even the same extract name does not make raw garlic, powder, oil or isolated SAC interchangeable with AGE.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N03 · Is the 1995 garlic preparation the same formulation as the AGE exposure in this epinephrine question?

Required materials and conditions: Actual ingredients, processing, product and specifications of the 1995 preparation and a mapping to S01 AGE
Conditions for verification: Actual material must verify formulation and ingredient identity between the 1995 garlic preparation and S01 AGE.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents another garlic preparation from being promoted to direct AGE replication or refutation.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N04 · Are the baseline status, eligibility and demographics of the actual epinephrine analysis population verified?

Required materials and conditions: S01 arm-specific age, sex, baseline platelet function, eligibility/exclusions and medication-use tables
Conditions for verification: Link actual epinephrine specimen population characteristics and eligibility to S01's analysis population.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: A title-level description of mainly healthy adults cannot establish representation of a particular patient or co-medication group.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N05 · Are the nominal dose list and the actual dose and intake for the epinephrine result linked?

Required materials and conditions: Arm-specific planned doses, actual intake, adherence data and dose mapping for the epinephrine result cell
Conditions for verification: Link each actual dose to its epinephrine result, comparator and time point; a nominal list alone does not establish a particular cell.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents automatic attribution of a shared dose list or another agonist's dose signal to this result.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N06 · Are exposure duration and the interval from the last dose to epinephrine blood collection and testing verified?

Required materials and conditions: S01 start/end dates, actual weeks of exposure, last-dose/blood-draw interval and testing time
Conditions for verification: Verify actual exposure duration and blood-draw/testing intervals by arm for the selected epinephrine analysis.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents short-term wording from becoming a specific number of weeks or a pharmacokinetic testing time.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N07 · Are the placebo's actual composition and common management verified for the epinephrine comparison?

Required materials and conditions: Placebo composition, dosing schedule, diet/management and arm differences
Conditions for verification: Link placebo composition, schedule, common management and the actual comparison of interest to arm-specific data.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: A placebo label alone cannot establish that AGE was the only difference.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N08 · Are the actual randomization, blinding and design procedures verified?

Required materials and conditions: Methods for sequence generation/concealment, parallel/crossover structure, blinding maintenance and baseline balance
Conditions for verification: Link S01's actual design, allocation/concealment and blinding methods to the epinephrine results.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents a randomized double-blind summary from being read as proof of no allocation error.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N09 · Can information on concomitant drugs, diet, adherence and exposure deviations affecting the epinephrine difference be verified?

Required materials and conditions: Arm-specific anticoagulants/antiplatelets, diet, rescue treatment, adherence/discontinuation and analysis handling
Conditions for verification: Link actual co-exposure, adherence, deviations and their handling to the epinephrine result population.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This keeps simultaneous exposures affecting platelet function separate from the selected intervention's contribution.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N10 · Are the exact measure, unit and direction of the epinephrine result verified?

Required materials and conditions: Original epinephrine result tables, threshold/maximum-aggregation definitions, units and positive cells
Conditions for verification: Link the selected epinephrine measure, unit and direction to the original table without substituting another measure.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: Agonists and measures represent different analyses; the aggregation label alone does not imply the same effect.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N11 · Are epinephrine concentration, specimen processing, equipment and repeated-specimen structure verified?

Required materials and conditions: Agonist concentration, PRP/specimen processing, equipment, measurement time and repeat/specimen identifiers
Conditions for verification: Verify the concentration, specimen/equipment and repeat structure of the selected epinephrine response.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents assuming that participant counts equal specimen counts or concentration-specific repeats.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N12 · Which between-arm contrast and analysis population does the selected epinephrine value estimate?

Required materials and conditions: Baseline change/end values, between/within-arm comparisons, ITT/PP, models and dose/concentration-specific repeat handling
Conditions for verification: Verify the actual analysis, denominator, model and measure definition for the between-arm contrast of interest.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents converting a directional summary into a formal placebo contrast or adjusted effect.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N13 · Can the original 34 people be distinguished from dose-specific epinephrine allocation, measurement and analysis denominators?

Required materials and conditions: Flow of total recruitment/allocation, dose/control-specific measured/analyzed people and specimen counts
Conditions for verification: Use actual material to distinguish the original 34-person sample description from dose/control and epinephrine analysis denominators.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents dividing a shared trial total into dose/endpoint analysis n or adding it across three tables.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N14 · Are missingness, losses, failed measurements and their handling verified for the epinephrine analysis?

Required materials and conditions: Dose-arm loss reasons, specimen/result missingness, analysis exclusions, imputation/sensitivity analyses
Conditions for verification: Link selected epinephrine measurement/analysis losses and their handling to the actual flow.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: The 34-person count and directional summary cannot establish that everyone was measured and analyzed.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N15 · Are the formal epinephrine effect estimate, variance, P value and confidence interval verified?

Required materials and conditions: Dose/concentration/time-specific arm values, SD/SE, between-arm estimate, P/CI and denominators
Conditions for verification: Link the formal epinephrine estimate and variance/interval to the corresponding analysis cell.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents partial reduction or a weak signal from establishing magnitude, precision or significance.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N16 · Do the registered/protocol/SAP prespecified epinephrine endpoint and report agree?

Required materials and conditions: S01 actual registration identifier, protocol, SAP, dates/versions and analysis hierarchy
Conditions for verification: Compare prespecified epinephrine endpoints, doses, concentrations, time points and analyses with results.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: Planning material is needed to examine possible selection of favorable findings among multiple agonists.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N17 · Are the testing scope and adjustment for multiple doses, agonists, concentrations/time points verified?

Required materials and conditions: Testing family, prespecified primary/secondary endpoints, all analysis tables and multiplicity handling
Conditions for verification: Verify the selected epinephrine result's hierarchy within all testing and its actual handling.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents multiple responses from one shared trial from becoming independent confirmations.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N18 · Can the reported epinephrine direction be verified down to the actual measure and dose cell?

Required materials and conditions: All favorable/no-difference/unfavorable cells of the selected response and exact analysis locations
Conditions for verification: Retain the original direction while verifying its epinephrine measure, dose, concentration and time-point cell.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents a positive direction from becoming a claim of effects at every dose and concentration.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N19 · Has S02's current null result been kept separate from direct epinephrine results?

Required materials and conditions: S02's actual endpoint list and records of whether a selected epinephrine result exists
Conditions for verification: Distinguish ADP, PAF and collagen in the current S02 list from the absence of epinephrine, and do not assign it as direct counterevidence.
Requirement and applicability: Required
Application exceptions: Met in this row is limited to distinguishing the attribution of the current report. Whether direct replication exists is assessed in separate replication and unique-participant conditions.
Why this condition is needed: This is needed to avoid transferring a null result for another agonist as counterevidence for the selected response.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N20 · Are the AGE/epinephrine original trials and results in the 2022 review verified?

Required materials and conditions: Review included-trial table and mapping of formulation, agonist, dose, population and endpoint to original results
Conditions for verification: Distinguish the review's directly relevant AGE/epinephrine trials using the actual included-trial table.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents reusing 12 RCTs and 595 people as the direct trials/denominator for this specific AGE response.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N21 · Are independent replication and unique participant counts for the same epinephrine/AGE question verified?

Required materials and conditions: Report/original-trial/cohort, included-trial overlap and response-specific analysis mapping
Conditions for verification: Verify matching formulation, response and comparison relationships for unique trials/participants using actual linking material.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents counting the shared 34-person trial, a related-preparation trial and a review as independent replications or unique-participant totals.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N22 · Are important-difference and interpretation criteria justified for this epinephrine measure?

Required materials and conditions: Measure-specific prespecified important difference, assay reproducibility/variation, rationale and original intervals
Conditions for verification: Verify the important-difference rationale for the selected measure together with the reported interval.
Requirement and applicability: Required
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: A weak/partial direction without numbers cannot establish an important or sufficient effect.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N23 · Is the boundary between the selected ex vivo epinephrine response and clinical thrombosis/bleeding events distinguished?

Required materials and conditions: A record linking the experimental endpoint to the scope of clinical-event/alternative-treatment claims
Conditions for verification: Keep the selected experimental endpoint separate from unmeasured clinical thrombosis/bleeding questions.
Requirement and applicability: Supplementary; required for clinical-event extensions
Application exceptions: Clinical-event trials are not universally required to verify the narrow experimental response. Clinical extension claims need separate direct material.
Why this condition is needed: This prevents a specimen response from becoming thrombosis prevention, thrombolysis, aspirin replacement or bleeding safety.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N24 · Is the current scope of PAF, arachidonic acid and other responses distinguished from the epinephrine result?

Required materials and conditions: Current agonist-specific report lists, unverified PAF formulation identity and the AA result gap
Conditions for verification: Keep S02 PAF as context with unverified identity and AA as a result gap named only in the crux; do not combine them with the selected response.
Requirement and applicability: Required
Application exceptions: This criterion checks only the current reporting scope. Successful distinction here does not satisfy actual PAF/AA material requirements.
Why this condition is needed: This prevents transferring adjacent agonist names or another preparation's results to the selected epinephrine result.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N25 · Is there direct material on optimal dose, long-term persistence and epinephrine response after discontinuation?

Required materials and conditions: Prespecified between-dose comparisons, exposure/withdrawal follow-up, long-term epinephrine results and interactions
Conditions for verification: Verify direct comparison and follow-up material matching the extension question.
Requirement and applicability: Supplementary; required for dose/persistence extensions
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents some short-term multi-dose directions from becoming an optimal-dose or persistent-effect claim.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N26 · Are actual bleeding, adverse-event and discontinuation collection data verified for the same AGE exposure?

Required materials and conditions: Event definitions, active/spontaneous collection, timing, exposure/denominators, severity and discontinuation tables
Conditions for verification: Link actual harm events, collection methods, exposure duration, denominators and discontinuation outcomes to the same population/exposure.
Requirement and applicability: Supplementary; required for harm interpretation
Application exceptions: Separate this experimental aggregation comparison from actual harms. Unverified event material does not mean 0 adverse events, safety or absence of experimental results.
Why this condition is needed: This prevents platelet responses or warning sentences from becoming actual adverse-event collection results or safety certification.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N27 · Is direct harm information verified for anticoagulant/antiplatelet co-use, bleeding disorders and surgical populations?

Required materials and conditions: Exposure, baseline risk, duration, harm events and comparison material in vulnerable/co-medication groups
Conditions for verification: Verify direct exposure/event material and interaction information for each relevant group.
Requirement and applicability: Supplementary; required for vulnerable-group safety extensions
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents extrapolating responses mainly from healthy adults to safety in high-risk populations.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N28 · Are actual funding, product support and employment/COI disclosures verified for the epinephrine material?

Required materials and conditions: Original S01/S02 funding, product support, author employment/patents/COI and S03 included-trial material
Conditions for verification: Check actual disclosures and product-support scope separately for each report/original trial.
Requirement and applicability: Supplementary; required for independence claims
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Why this condition is needed: This prevents an original independent-summary label or academic-research wording from establishing independent funding or no product provision.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N29 · Are study-family and review-recitation relationships for the three reports and shared epinephrine results stated?

Required materials and conditions: Verified/unverified relationships among 3 reports, PMID/DOI, shared trials and review inclusion
Conditions for verification: Record the shared 34-person S01 trial, related S02 preparation, S03 review and uncertain inclusion relationships separately.
Requirement and applicability: Required
Application exceptions: This evaluates only the distinction of recorded relationships. Success does not establish direct replication or unique study counts.
Why this condition is needed: Bibliographic record counts must be distinguished from independent study counts.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N30 · Are the original broad C46, all axes and the English-placeholder correction event preserved?

Required materials and conditions: The complete original record, both languages, axes, empty arrays/strings and original correction location/date
Conditions for verification: Preserve original grade/score/axes, both languages and correction wording in their original types; create no separate epinephrine grade.
Requirement and applicability: Required
Application exceptions: This is a preservation criterion and does not satisfy unverified clinical-material requirements in other items.
Why this condition is needed: This prevents using historical scores to determine condition status or promoting generic verification English into actual analysis values.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N31 · Are the original review date, correction date and current review scope distinguished?

Required materials and conditions: Original verdict-review date, correction event, currently read inputs and records of absent cut-off/access fields
Conditions for verification: Distinguish local retained-record conversion from historical review/correction; do not infer absent cut-off or access dates.
Requirement and applicability: Required
Application exceptions: This criterion labels the sheet’s scope. It does not establish a successful new search or resolution of clinical gaps.
Why this condition is needed: This prevents backdating actual individual access or a latest search cut-off to the historical review date.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N32 · Are current local-summary reading and unread external gateways/full texts distinguished by material?

Required materials and conditions: Exact input locations/identity and actual actions for PubMed, DOI and full-text materials
Conditions for verification: Link local retained-record reading to actual locations; keep external material as not attempted/unread with false flags.
Requirement and applicability: Required
Application exceptions: External access not attempted is not access failure. Satisfying this recording criterion is separate from satisfying clinical-material requirements.
Why this condition is needed: This prevents an external link or historical verification wording from becoming current full-text reading.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

N33 · Is the remaining scope of external original-table, method and registration comparison stated?

Required materials and conditions: epinephrine original result tables, methods/appendices, actual registration/SAP identity and currently uncompared locations
Conditions for verification: Distinguish retained locations actually read from unread external original tables/methods/registration.
Requirement and applicability: Required
Application exceptions: This recording criterion states current review scope. Unperformed review is not promoted to a verified clinical comparison or safety.
Why this condition is needed: This prevents retained-record self-review from being read as original-paper/official-method execution or independent clinical certification.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Retained method-application records were reused. External originals were not reread and method content was not reassessed.

What the statuses mean

Met: The stated retained information, reading, attribution or counting boundary was checked within limits. This does not certify efficacy, safety, full-text reading or reassessment.
Partly verified: Some retained information was checked, but material or conditions required by the criterion remain unverified.
Unverified: The criterion cannot be established in the retained record. This does not mean 0 studies, an effect of 0 or absence of harm.
Not applicable: This is limited to a specific application exception. It does not substitute for unread material.
Review incomplete: Remaining comparison work and its reason are stated separately. This is distinguished from unverified material.

Change history

2026-10-26 · Public page/material version 1.0

The public view and materials were prepared from the existing 33 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (2026-10-05) and original evidence review date (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Is the epinephrine-induced ex vivo platelet aggregation linked as a separate question and distinguished from the original broad verdict?

Current findings: The original wording is reduced ex vivo platelet aggregation, and subclaims is an empty array. This table covers only the epinephrine-induced ex vivo platelet aggregation. C, 46 points and all axes are historical values of the broad parent.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: For this narrow record-boundary criterion, the original claim, empty array, agonist distinction and formal derived assignment are linked. This does not establish clinical efficacy.
Reason for missing information: No new individual grade or score is created; the separate grade remains unrecorded.
Required materials and conditions: A record linking the original verdict claim, empty subclaims, derived question and parent verdict
Materials to obtain first: A record linking the original verdict claim, empty subclaims, derived question and parent verdict
Further research: If the boundary changes, redefine the agonist, measure and comparison as a new question and preserve the previous version.
Remaining uncertainty: No new individual grade or score is created; the separate grade remains unrecorded. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Retain the original wording, identify the epinephrine-induced ex vivo platelet aggregation as a separate target, and state that the derived ID is not an original array index.
Why this condition is needed: This prevents biologically different agonist responses from being combined into one estimate or a new grade.
Application exceptions: Only this item evaluates the recorded boundary. Other items requiring actual dose, denominator and estimate material are assessed separately.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N02 · Are S01's actual AGE formulation and SAC specification verified for the epinephrine comparison?

Current findings: The original claim conditions describe AGE capsules and unverified trial-specific SAC specifications. Raw garlic, garlic powder, oil, allicin, black garlic, fermented garlic and isolated SAC are not interchangeable.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The nominal AGE capsule formulation is recorded, but actual product, batch and SAC specifications remain to be verified.
Reason for missing information: Product and SAC specifications remain unverified in the retained material.
Required materials and conditions: Original product name, aging process, capsule content, batch SAC specification and actual administration data
Materials to obtain first: Original product name, aging process, capsule content, batch SAC specification and actual administration data
Further research: In controlled studies with matching products and batches, link the administered substance and ingredient specifications to the analysis cell.
Remaining uncertainty: Product and SAC specifications remain unverified in the retained material. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link the actual AGE capsule product and ingredient specifications to the exposure used for epinephrine analysis.
Why this condition is needed: Even the same extract name does not make raw garlic, powder, oil or isolated SAC interchangeable with AGE.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N03 · Is the 1995 garlic preparation the same formulation as the AGE exposure in this epinephrine question?

Current findings: S02's title refers to a garlic preparation and a small sample of healthy men. The retained summary does not specify whether the preparation was aged, its product or specifications. The 1995 report's endpoints are ADP, PAF and collagen. The current retained summary contains no epinephrine result, so its null result is not assigned as direct counterevidence for epinephrine.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: S02 supplies related context, but original material confirming the same exposure as AGE is absent.
Reason for missing information: Unverified formulation identity is not a judgment about significance or worldwide absence of research.
Required materials and conditions: Actual ingredients, processing, product and specifications of the 1995 preparation and a mapping to S01 AGE
Materials to obtain first: Actual ingredients, processing, product and specifications of the 1995 preparation and a mapping to S01 AGE
Further research: After checking formulation identity, compare whether the epinephrine measure matches; retain a separate preparation question if identity differs.
Remaining uncertainty: Unverified formulation identity is not a judgment about significance or worldwide absence of research. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Actual material must verify formulation and ingredient identity between the 1995 garlic preparation and S01 AGE.
Why this condition is needed: This prevents another garlic preparation from being promoted to direct AGE replication or refutation.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S02

N04 · Are the baseline status, eligibility and demographics of the actual epinephrine analysis population verified?

Current findings: The claim conditions mainly concern healthy adults and treat antiplatelet co-use separately. S01 is summarized only as 34 people, without arm-specific demographics or baseline characteristics. S02's healthy-male information is not inherited by S01.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The original scope mainly concerns healthy adults, but S01's actual selection and arm-specific baseline data remain unverified.
Reason for missing information: Age, sex, baseline platelet values and selection remain unverified.
Required materials and conditions: S01 arm-specific age, sex, baseline platelet function, eligibility/exclusions and medication-use tables
Materials to obtain first: S01 arm-specific age, sex, baseline platelet function, eligibility/exclusions and medication-use tables
Further research: In studies reporting baseline characteristics, compare selection and arm balance alongside the epinephrine results.
Remaining uncertainty: Age, sex, baseline platelet values and selection remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link actual epinephrine specimen population characteristics and eligibility to S01's analysis population.
Why this condition is needed: A title-level description of mainly healthy adults cannot establish representation of a particular patient or co-medication group.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02

N05 · Are the nominal dose list and the actual dose and intake for the epinephrine result linked?

Current findings: The original dose list is 2.4, 4.8 and 7.2 g/day. Although the trial doses are 2.4, 4.8 and 7.2 g/day, no material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The dose list and a narrative clue for the selected response exist, but actual intake and result-cell mapping remain unverified.
Reason for missing information: Actual intake, arm-specific adherence and the exact dose cell for the positive/weak signal remain unverified.
Required materials and conditions: Arm-specific planned doses, actual intake, adherence data and dose mapping for the epinephrine result cell
Materials to obtain first: Arm-specific planned doses, actual intake, adherence data and dose mapping for the epinephrine result cell
Further research: After obtaining dose-specific comparison tables, analyze planned epinephrine dose comparisons separately from actual intake.
Remaining uncertainty: Actual intake, arm-specific adherence and the exact dose cell for the positive/weak signal remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link each actual dose to its epinephrine result, comparator and time point; a nominal list alone does not establish a particular cell.
Why this condition is needed: This prevents automatic attribution of a shared dose list or another agonist's dose signal to this result.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N06 · Are exposure duration and the interval from the last dose to epinephrine blood collection and testing verified?

Current findings: The claim conditions describe only short-term exposure with durations differing across trials. S01's actual duration, blood-draw timing and interval from the last dose are absent.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The short-term description alone cannot establish the required actual timeline.
Reason for missing information: Exact trial-specific duration and blood-draw/testing time remain unverified.
Required materials and conditions: S01 start/end dates, actual weeks of exposure, last-dose/blood-draw interval and testing time
Materials to obtain first: S01 start/end dates, actual weeks of exposure, last-dose/blood-draw interval and testing time
Further research: In comparisons with a defined timeline, record pre/post exposure and last-dose intervals under the same conditions.
Remaining uncertainty: Exact trial-specific duration and blood-draw/testing time remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify actual exposure duration and blood-draw/testing intervals by arm for the selected epinephrine analysis.
Why this condition is needed: This prevents short-term wording from becoming a specific number of weeks or a pharmacokinetic testing time.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N07 · Are the placebo's actual composition and common management verified for the epinephrine comparison?

Current findings: The claim conditions name placebo as comparator, and S01 is described as a placebo dose-ranging trial. Actual placebo composition, diet and arm-specific common management data are absent.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Nominal placebo control is identified, but actual composition, schedule and common management remain to be verified.
Reason for missing information: Placebo composition and common management remain unverified.
Required materials and conditions: Placebo composition, dosing schedule, diet/management and arm differences
Materials to obtain first: Placebo composition, dosing schedule, diet/management and arm differences
Further research: In placebo comparisons with matching management, examine arm-specific management changes in relation to epinephrine results.
Remaining uncertainty: Placebo composition and common management remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link placebo composition, schedule, common management and the actual comparison of interest to arm-specific data.
Why this condition is needed: A placebo label alone cannot establish that AGE was the only difference.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N08 · Are the actual randomization, blinding and design procedures verified?

Current findings: S01 is described as a randomized, double-blind, placebo-controlled dose-ranging trial. Actual sequence generation/concealment, parallel/crossover structure and blinding assessment data are absent.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The summary classifies the design, but actual conduct has not been verified.
Reason for missing information: Design structure, allocation/concealment, baseline balance and maintained blinding remain unverified.
Required materials and conditions: Methods for sequence generation/concealment, parallel/crossover structure, blinding maintenance and baseline balance
Materials to obtain first: Methods for sequence generation/concealment, parallel/crossover structure, blinding maintenance and baseline balance
Further research: After comparing methods, assess allocation and specimen evaluation blinding according to the actual design.
Remaining uncertainty: Design structure, allocation/concealment, baseline balance and maintained blinding remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link S01's actual design, allocation/concealment and blinding methods to the epinephrine results.
Why this condition is needed: This prevents a randomized double-blind summary from being read as proof of no allocation error.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N09 · Can information on concomitant drugs, diet, adherence and exposure deviations affecting the epinephrine difference be verified?

Current findings: The original population scope treats antiplatelet co-use separately and gives safety warnings. S01's actual co-medication, adherence, rescue/discontinuation data remain unverified.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Background-risk warnings exist but do not replace actual arm-specific exposure records.
Reason for missing information: Arm-specific co-exposure, adherence and deviations in relation to the effect of interest remain unverified.
Required materials and conditions: Arm-specific anticoagulants/antiplatelets, diet, rescue treatment, adherence/discontinuation and analysis handling
Materials to obtain first: Arm-specific anticoagulants/antiplatelets, diet, rescue treatment, adherence/discontinuation and analysis handling
Further research: In comparisons recording actual co-medication and deviations, review them according to the effect of interest and analysis handling.
Remaining uncertainty: Arm-specific co-exposure, adherence and deviations in relation to the effect of interest remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link actual co-exposure, adherence, deviations and their handling to the epinephrine result population.
Why this condition is needed: This keeps simultaneous exposures affecting platelet function separate from the selected intervention's contribution.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N10 · Are the exact measure, unit and direction of the epinephrine result verified?

Current findings: S01's selected clue is a partial reduction in epinephrine-induced aggregation. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the corresponding analysis cell remain unverified. The representative endpoint in the claim conditions broadly includes maximum aggregation or threshold.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: A directional or threshold clue exists, but the unit, definition and original analysis cell remain to be verified.
Reason for missing information: The exact measure, unit, threshold definition and analysis cell remain unverified.
Required materials and conditions: Original epinephrine result tables, threshold/maximum-aggregation definitions, units and positive cells
Materials to obtain first: Original epinephrine result tables, threshold/maximum-aggregation definitions, units and positive cells
Further research: Fix the epinephrine measure and unit from the original result table before comparing between-arm results on the same measure.
Remaining uncertainty: The exact measure, unit, threshold definition and analysis cell remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link the selected epinephrine measure, unit and direction to the original table without substituting another measure.
Why this condition is needed: Agonists and measures represent different analyses; the aggregation label alone does not imply the same effect.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N11 · Are epinephrine concentration, specimen processing, equipment and repeated-specimen structure verified?

Current findings: The original material summarizes agonist-specific ex vivo aggregation but does not give epinephrine concentration, specimen processing, equipment or specimen repeat counts.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Without actual analysis conditions, effects of concentration or assay method cannot be compared.
Reason for missing information: Concentration, specimen preparation, equipment, measurement window and repeated-specimen counts remain unverified.
Required materials and conditions: Agonist concentration, PRP/specimen processing, equipment, measurement time and repeat/specimen identifiers
Materials to obtain first: Agonist concentration, PRP/specimen processing, equipment, measurement time and repeat/specimen identifiers
Further research: Specify matching concentration, specimen processing and assay methods, and design comparisons accounting for within-person repeats.
Remaining uncertainty: Concentration, specimen preparation, equipment, measurement window and repeated-specimen counts remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify the concentration, specimen/equipment and repeat structure of the selected epinephrine response.
Why this condition is needed: This prevents assuming that participant counts equal specimen counts or concentration-specific repeats.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N12 · Which between-arm contrast and analysis population does the selected epinephrine value estimate?

Current findings: S01's result is a directional summary of a partial reduction in epinephrine-induced aggregation. Whether it is a within-arm change or a placebo comparison, end value/change, ITT/PP or adjusted/unadjusted model is unverified in the current material.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The directional summary lacks the required formal contrast and analysis definition. Valid unadjusted comparisons are allowed; adjustment is not universally required.
Reason for missing information: Between-arm estimate, analysis population, model and repeat-handling definitions remain unverified.
Required materials and conditions: Baseline change/end values, between/within-arm comparisons, ITT/PP, models and dose/concentration-specific repeat handling
Materials to obtain first: Baseline change/end values, between/within-arm comparisons, ITT/PP, models and dose/concentration-specific repeat handling
Further research: Compare the original analysis or an appropriate comparison model specifying the between-arm contrast; retain within-arm change separately.
Remaining uncertainty: Between-arm estimate, analysis population, model and repeat-handling definitions remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify the actual analysis, denominator, model and measure definition for the between-arm contrast of interest.
Why this condition is needed: This prevents converting a directional summary into a formal placebo contrast or adjusted effect.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N13 · Can the original 34 people be distinguished from dose-specific epinephrine allocation, measurement and analysis denominators?

Current findings: S01 reports n as 34 people. Whether this is recruitment, allocation, completion or analysis and each arm's epinephrine analysis count remain unverified. Three tables share the same 34-person trial.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The reported 34 people are identified, but actual dose/endpoint denominators are absent. They were not filled by division or addition.
Reason for missing information: Allocation, completion and analysis stages and arm/concentration-specific person/specimen counts remain unverified.
Required materials and conditions: Flow of total recruitment/allocation, dose/control-specific measured/analyzed people and specimen counts
Materials to obtain first: Flow of total recruitment/allocation, dose/control-specific measured/analyzed people and specimen counts
Further research: Compare person/specimen identifier flow and state the analysis unit and arm-specific denominators.
Remaining uncertainty: Allocation, completion and analysis stages and arm/concentration-specific person/specimen counts remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Use actual material to distinguish the original 34-person sample description from dose/control and epinephrine analysis denominators.
Why this condition is needed: This prevents dividing a shared trial total into dose/endpoint analysis n or adding it across three tables.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N14 · Are missingness, losses, failed measurements and their handling verified for the epinephrine analysis?

Current findings: Beyond 34 people, the current evidence table has no actual loss, specimen-failure or analysis-exclusion counts or handling. Generic English sample-size wording is not actual denominator data.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Loss/missingness data are absent, so handling cannot be verified; losses were not filled as 0.
Reason for missing information: Loss counts, reasons, handling and sensitivity analyses remain unverified.
Required materials and conditions: Dose-arm loss reasons, specimen/result missingness, analysis exclusions, imputation/sensitivity analyses
Materials to obtain first: Dose-arm loss reasons, specimen/result missingness, analysis exclusions, imputation/sensitivity analyses
Further research: Review how missingness affects the contrast of interest using original data recording the types of omission.
Remaining uncertainty: Loss counts, reasons, handling and sensitivity analyses remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link selected epinephrine measurement/analysis losses and their handling to the actual flow.
Why this condition is needed: The 34-person count and directional summary cannot establish that everyone was measured and analyzed.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N15 · Are the formal epinephrine effect estimate, variance, P value and confidence interval verified?

Current findings: The selected direction is a partial reduction in epinephrine-induced aggregation, but actual arm values, SD/SE, P and CI are absent from current evidence/citation summaries. No new difference, variance or interval is calculated.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Numerical data needed for the estimate and precision are absent, so verification is not possible.
Reason for missing information: Arm values, SD/SE, formal estimate, P, CI and denominators remain unverified.
Required materials and conditions: Dose/concentration/time-specific arm values, SD/SE, between-arm estimate, P/CI and denominators
Materials to obtain first: Dose/concentration/time-specific arm values, SD/SE, between-arm estimate, P/CI and denominators
Further research: Obtain original estimates and intervals on the same epinephrine measure to compare magnitude and uncertainty.
Remaining uncertainty: Arm values, SD/SE, formal estimate, P, CI and denominators remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link the formal epinephrine estimate and variance/interval to the corresponding analysis cell.
Why this condition is needed: This prevents partial reduction or a weak signal from establishing magnitude, precision or significance.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N16 · Do the registered/protocol/SAP prespecified epinephrine endpoint and report agree?

Current findings: S01's registration field says not verified. Original plans, registration number, SAP and time-specific prespecified epinephrine definitions are absent. Non-acquisition does not establish non-registration or selective reporting.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Without prior planning material, adherence to the actual plan cannot be checked.
Reason for missing information: Registration/SAP identity and planned endpoints/analyses remain unverified.
Required materials and conditions: S01 actual registration identifier, protocol, SAP, dates/versions and analysis hierarchy
Materials to obtain first: S01 actual registration identifier, protocol, SAP, dates/versions and analysis hierarchy
Further research: Compare dated plans and result tables to distinguish prespecified from post hoc analyses of the selected response.
Remaining uncertainty: Registration/SAP identity and planned endpoints/analyses remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Compare prespecified epinephrine endpoints, doses, concentrations, time points and analyses with results.
Why this condition is needed: Planning material is needed to examine possible selection of favorable findings among multiple agonists.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N17 · Are the testing scope and adjustment for multiple doses, agonists, concentrations/time points verified?

Current findings: The manuscript notes multiple doses and agonists in the positive trial; S01's evidence weight notes multiplicity and a small sample. Actual test counts, concentration/time lists and adjustment status are absent.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Multiplicity is identified as a limitation, but the actual hierarchy, testing family and handling remain unverified.
Reason for missing information: Prespecified hierarchy, complete test list and adjustment/reporting methods remain unverified.
Required materials and conditions: Testing family, prespecified primary/secondary endpoints, all analysis tables and multiplicity handling
Materials to obtain first: Testing family, prespecified primary/secondary endpoints, all analysis tables and multiplicity handling
Further research: Examine multiple contrasts and selective reporting in plan-based analyses disclosing all results.
Remaining uncertainty: Prespecified hierarchy, complete test list and adjustment/reporting methods remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify the selected epinephrine result's hierarchy within all testing and its actual handling.
Why this condition is needed: This prevents multiple responses from one shared trial from becoming independent confirmations.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N18 · Can the reported epinephrine direction be verified down to the actual measure and dose cell?

Current findings: S01 and S01's citation summary indicate a partial reduction in epinephrine-induced aggregation. Although the trial doses are 2.4, 4.8 and 7.2 g/day, no material links a positive epinephrine cell to a dose value. The highest-dose ADP clue is not transferred to epinephrine. Only the direction of partial reduction is recorded; whether the measure is maximum aggregation or threshold and the corresponding analysis cell remain unverified.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The direction is retained, but numerical results and conditions for all cells have not been verified.
Reason for missing information: The exact positive/weak-signal cell and results in the remaining cells remain unverified.
Required materials and conditions: All favorable/no-difference/unfavorable cells of the selected response and exact analysis locations
Materials to obtain first: All favorable/no-difference/unfavorable cells of the selected response and exact analysis locations
Further research: Compare all prespecified epinephrine dose/concentration cells, including cells without favorable results.
Remaining uncertainty: The exact positive/weak-signal cell and results in the remaining cells remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Retain the original direction while verifying its epinephrine measure, dose, concentration and time-point cell.
Why this condition is needed: This prevents a positive direction from becoming a claim of effects at every dose and concentration.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N19 · Has S02's current null result been kept separate from direct epinephrine results?

Current findings: S02 lists ADP, PAF and collagen aggregation and describes no significant oral effect. The current summary contains no epinephrine result. Its formulation has also not been confirmed as identical to AGE.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This row asks about the attribution scope of the current report. The other listed responses were distinguished from epinephrine.
Reason for missing information: This does not establish that the entire external original paper did not report epinephrine.
Required materials and conditions: S02's actual endpoint list and records of whether a selected epinephrine result exists
Materials to obtain first: S02's actual endpoint list and records of whether a selected epinephrine result exists
Further research: If new original material contains an epinephrine analysis, compare its formulation, measure and actual result separately.
Remaining uncertainty: This does not establish that the entire external original paper did not report epinephrine. No new values, denominators, CI, P or grades are calculated or reassessed.
Conditions for verification: Distinguish ADP, PAF and collagen in the current S02 list from the absence of epinephrine, and do not assign it as direct counterevidence.
Why this condition is needed: This is needed to avoid transferring a null result for another agonist as counterevidence for the selected response.
Application exceptions: Met in this row is limited to distinguishing the attribution of the current report. Whether direct replication exists is assessed in separate replication and unique-participant conditions.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S02

N20 · Are the AGE/epinephrine original trials and results in the 2022 review verified?

Current findings: S03 summarizes 12 RCTs and 595 people, with 6 positive and the rest null; heterogeneity prevents a firm conclusion. Individual formulations, agonists and inclusion of S01/S02 are absent from the retained material.
Verification status: Partly verified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The review's overall scope and directional heterogeneity are recorded, but the trial list matching this response remains unverified.
Reason for missing information: Selected AGE/epinephrine trial counts, participant counts and original-table mappings remain unverified.
Required materials and conditions: Review included-trial table and mapping of formulation, agonist, dose, population and endpoint to original results
Materials to obtain first: Review included-trial table and mapping of formulation, agonist, dose, population and endpoint to original results
Further research: Compare included trials with original reports, separate formulation/response-specific results and identify participant overlap.
Remaining uncertainty: Selected AGE/epinephrine trial counts, participant counts and original-table mappings remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Distinguish the review's directly relevant AGE/epinephrine trials using the actual included-trial table.
Why this condition is needed: This prevents reusing 12 RCTs and 595 people as the direct trials/denominator for this specific AGE response.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S03

N21 · Are independent replication and unique participant counts for the same epinephrine/AGE question verified?

Current findings: S01 is a shared 34-person trial. S02's AGE identity and S03's included-trial relationships remain unverified. The 34 and 595 people are not added, and three tables are not counted as three independent trials.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Material establishing matching replication and unique participant counts is absent.
Reason for missing information: Unique direct replication and participant counts remain unrecorded.
Required materials and conditions: Report/original-trial/cohort, included-trial overlap and response-specific analysis mapping
Materials to obtain first: Report/original-trial/cohort, included-trial overlap and response-specific analysis mapping
Further research: After checking actual study families and included-trial overlap, examine replication of the same epinephrine question.
Remaining uncertainty: Unique direct replication and participant counts remain unrecorded. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify matching formulation, response and comparison relationships for unique trials/participants using actual linking material.
Why this condition is needed: This prevents counting the shared 34-person trial, a related-preparation trial and a review as independent replications or unique-participant totals.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N22 · Are important-difference and interpretation criteria justified for this epinephrine measure?

Current findings: The selected manuscript response is a partial reduction in epinephrine-induced aggregation, without important-difference criteria, assay reproducibility or CI data. No arbitrary MCID, minimum n or required weeks are created.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Without importance criteria and precision data, adequacy cannot be verified.
Reason for missing information: The relationship between important-difference rationale, measurement variation and intervals remains unverified.
Required materials and conditions: Measure-specific prespecified important difference, assay reproducibility/variation, rationale and original intervals
Materials to obtain first: Measure-specific prespecified important difference, assay reproducibility/variation, rationale and original intervals
Further research: Specify reproducibility and a justified important difference for the measure, then compare them with formal estimates and intervals.
Remaining uncertainty: The relationship between important-difference rationale, measurement variation and intervals remains unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify the important-difference rationale for the selected measure together with the reported interval.
Why this condition is needed: A weak/partial direction without numbers cannot establish an important or sufficient effect.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N23 · Is the boundary between the selected ex vivo epinephrine response and clinical thrombosis/bleeding events distinguished?

Current findings: The original explanation states that clinical thrombosis and bleeding were not measured, and its advertising guidance excludes thrombosis prevention, thrombolysis, aspirin replacement and bleeding-safety claims. Only the selected epinephrine experimental response is covered.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks about the established endpoint boundary. Experimental response and clinical events are separated; clinical efficacy is not established.
Reason for missing information: Clinical-event effects and safety are not established by this table's experimental endpoint.
Required materials and conditions: A record linking the experimental endpoint to the scope of clinical-event/alternative-treatment claims
Materials to obtain first: A record linking the experimental endpoint to the scope of clinical-event/alternative-treatment claims
Further research: If clinical events are the question, examine them in separate comparisons with suitable populations, follow-up and event collection.
Remaining uncertainty: Clinical-event effects and safety are not established by this table's experimental endpoint. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Keep the selected experimental endpoint separate from unmeasured clinical thrombosis/bleeding questions.
Why this condition is needed: This prevents a specimen response from becoming thrombosis prevention, thrombolysis, aspirin replacement or bleeding safety.
Application exceptions: Clinical-event trials are not universally required to verify the narrow experimental response. Clinical extension claims need separate direct material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N24 · Is the current scope of PAF, arachidonic acid and other responses distinguished from the epinephrine result?

Current findings: The original crux distinguishes ADP, collagen, epinephrine and arachidonic acid. S02 includes PAF, but its AGE identity is unverified. Direct AA results are not linked in the 3 evidence/3 citation entries. These gaps remain in related PAF/arachidonic acid questions and the parent context.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks about distinguishing the current reporting scope. Adjacent responses and result gaps are retained without adding them to the selected epinephrine estimate.
Reason for missing information: This does not prove worldwide absence of research or an effect of 0 for PAF/AA.
Required materials and conditions: Current agonist-specific report lists, unverified PAF formulation identity and the AA result gap
Materials to obtain first: Current agonist-specific report lists, unverified PAF formulation identity and the AA result gap
Further research: When new original material for each response appears, define formulation, measure, concentration and comparator separately and examine it in a separate table version.
Remaining uncertainty: This does not prove worldwide absence of research or an effect of 0 for PAF/AA. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Keep S02 PAF as context with unverified identity and AA as a result gap named only in the crux; do not combine them with the selected response.
Why this condition is needed: This prevents transferring adjacent agonist names or another preparation's results to the selected epinephrine result.
Application exceptions: This criterion checks only the current reporting scope. Successful distinction here does not satisfy actual PAF/AA material requirements.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N25 · Is there direct material on optimal dose, long-term persistence and epinephrine response after discontinuation?

Current findings: The original exposure is short-term and varies by trial; only a partial reduction in epinephrine-induced aggregation is retained. Direct long-term, post-withdrawal and optimal-dose material is absent.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The original dose-ranging direction and short-term material cannot answer extension questions.
Reason for missing information: Long-term/withdrawal follow-up, optimal-dose comparisons and interactions remain unverified.
Required materials and conditions: Prespecified between-dose comparisons, exposure/withdrawal follow-up, long-term epinephrine results and interactions
Materials to obtain first: Prespecified between-dose comparisons, exposure/withdrawal follow-up, long-term epinephrine results and interactions
Further research: If persistence or dose optimization is the objective, design separate prespecified dose comparisons and withdrawal/long-term follow-up.
Remaining uncertainty: Long-term/withdrawal follow-up, optimal-dose comparisons and interactions remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify direct comparison and follow-up material matching the extension question.
Why this condition is needed: This prevents some short-term multi-dose directions from becoming an optimal-dose or persistent-effect claim.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01

N26 · Are actual bleeding, adverse-event and discontinuation collection data verified for the same AGE exposure?

Current findings: The original safety category is Warning, concerning unsupervised use with anticoagulants, antiplatelets, bleeding disorders and around surgery. Actual bleeding-event counts, collection, discontinuations and denominators are absent from the evidence table.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The warning scope is identified, but actual event-collection and harm-estimate data remain unverified.
Reason for missing information: Harm diagnosis, collection, timeline, denominators and discontinuation data remain unverified.
Required materials and conditions: Event definitions, active/spontaneous collection, timing, exposure/denominators, severity and discontinuation tables
Materials to obtain first: Event definitions, active/spontaneous collection, timing, exposure/denominators, severity and discontinuation tables
Further research: For harm questions, examine separate material with event definitions, collection systems and appropriate follow-up.
Remaining uncertainty: Harm diagnosis, collection, timeline, denominators and discontinuation data remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link actual harm events, collection methods, exposure duration, denominators and discontinuation outcomes to the same population/exposure.
Why this condition is needed: This prevents platelet responses or warning sentences from becoming actual adverse-event collection results or safety certification.
Application exceptions: Separate this experimental aggregation comparison from actual harms. Unverified event material does not mean 0 adverse events, safety or absence of experimental results.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N27 · Is direct harm information verified for anticoagulant/antiplatelet co-use, bleeding disorders and surgical populations?

Current findings: The manuscript warns these groups and treats antiplatelet co-use separately. Actual harm comparisons, denominators and long-term follow-up for each group are absent from the retained evidence table.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: The caution scope exists, but direct vulnerable-group material is absent, so harm magnitude or safety cannot be verified.
Reason for missing information: Direct material on vulnerable-group, co-medication/long-term harms and interactions remains unverified.
Required materials and conditions: Exposure, baseline risk, duration, harm events and comparison material in vulnerable/co-medication groups
Materials to obtain first: Exposure, baseline risk, duration, harm events and comparison material in vulnerable/co-medication groups
Further research: For co-medication/vulnerable-group questions, use suitable separate comparison/follow-up designs recording baseline risk and actual exposure.
Remaining uncertainty: Direct material on vulnerable-group, co-medication/long-term harms and interactions remains unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Verify direct exposure/event material and interaction information for each relevant group.
Why this condition is needed: This prevents extrapolating responses mainly from healthy adults to safety in high-risk populations.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N28 · Are actual funding, product support and employment/COI disclosures verified for the epinephrine material?

Current findings: S01 records unverified product-support details, S02 unverified funding, and S03 academic research with mixed original-trial funding. Actual employment, product provision, COI wording and original-trial funding are absent.
Verification status: Unverified
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: Unverified support details cannot establish independence or absence of conflicts.
Reason for missing information: Product support, authors/institutions, COI and review original-trial funding remain unverified.
Required materials and conditions: Original S01/S02 funding, product support, author employment/patents/COI and S03 included-trial material
Materials to obtain first: Original S01/S02 funding, product support, author employment/patents/COI and S03 included-trial material
Further research: Compare original disclosures and interpret results separately from study families and product support.
Remaining uncertainty: Product support, authors/institutions, COI and review original-trial funding remain unverified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Check actual disclosures and product-support scope separately for each report/original trial.
Why this condition is needed: This prevents an original independent-summary label or academic-research wording from establishing independent funding or no product provision.
Application exceptions: This criterion requires actual material verification for the epinephrine-induced ex vivo platelet aggregation. Values for other agonists, formulations or doses, or successful preservation, do not replace the required actual material.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N29 · Are study-family and review-recitation relationships for the three reports and shared epinephrine results stated?

Current findings: S01 PMID 11238801 is one multi-dose/response trial. S02 PMID 8582091 reports another garlic preparation; S03 PMID 36222178 is a 12-RCT review. Actual review inclusion remains unverified.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks for an honest verified/unverified distinction in family attribution records. Direct independent replication counts remain unverified in the separate unique-replication criterion.
Reason for missing information: Unverified review/original-trial inclusion and unique-participant totals are retained.
Required materials and conditions: Verified/unverified relationships among 3 reports, PMID/DOI, shared trials and review inclusion
Materials to obtain first: Verified/unverified relationships among 3 reports, PMID/DOI, shared trials and review inclusion
Further research: Compare original trial identifiers with included-trial tables and update links when new overlap relationships are found.
Remaining uncertainty: Unverified review/original-trial inclusion and unique-participant totals are retained. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Record the shared 34-person S01 trial, related S02 preparation, S03 review and uncertain inclusion relationships separately.
Why this condition is needed: Bibliographic record counts must be distinguished from independent study counts.
Application exceptions: This evaluates only the distinction of recorded relationships. Success does not establish direct replication or unique study counts.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N30 · Are the original broad C46, all axes and the English-placeholder correction event preserved?

Current findings: Original C, 46 points, B/S/R0/I1/EX/B2/CX and empty subclaims/deliberation are preserved. The original verdict-review date is 2026-09-08 and the correction event is 2026-09-14. The correction describes replacing English placeholders, but some current evidence English remains generic verification wording. These strings are also retained and are not used as actual n/P/CI.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks about preserving original values and the correction event. Complete original material and types are retained without creating effects, grades or English clinical values.
Reason for missing information: The correction event and original review date are not report-specific full-text access dates.
Required materials and conditions: The complete original record, both languages, axes, empty arrays/strings and original correction location/date
Materials to obtain first: The complete original record, both languages, axes, empty arrays/strings and original correction location/date
Further research: For future corrections, separate the before-text, event, new version and reason, then compare related observations/conditions.
Remaining uncertainty: The correction event and original review date are not report-specific full-text access dates. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Preserve original grade/score/axes, both languages and correction wording in their original types; create no separate epinephrine grade.
Why this condition is needed: This prevents using historical scores to determine condition status or promoting generic verification English into actual analysis values.
Application exceptions: This is a preservation criterion and does not satisfy unverified clinical-material requirements in other items.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N31 · Are the original review date, correction date and current review scope distinguished?

Current findings: The original review date is 2026-09-08 and the correction date is 2026-09-14. Original search-cut-off and report-specific access-date/reading-scope fields are absent. This review date is 2026-10-05; all current inputs were read without new external searches or full-text reading.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks about date/scope labeling. Different events are distinguished and absent individual access dates remain unrecorded.
Reason for missing information: No latest comprehensive literature search or verification of worldwide research absence was performed.
Required materials and conditions: Original verdict-review date, correction event, currently read inputs and records of absent cut-off/access fields
Materials to obtain first: Original verdict-review date, correction event, currently read inputs and records of absent cut-off/access fields
Further research: If new material is permitted, add search/access/review dates and actual locations as separate events.
Remaining uncertainty: No latest comprehensive literature search or verification of worldwide research absence was performed. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Distinguish local retained-record conversion from historical review/correction; do not infer absent cut-off or access dates.
Why this condition is needed: This prevents backdating actual individual access or a latest search cut-off to the historical review date.
Application exceptions: This criterion labels the sheet’s scope. It does not establish a successful new search or resolution of clinical gaps.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N32 · Are current local-summary reading and unread external gateways/full texts distinguished by material?

Current findings: The complete current retained source, Korean/English, 3 evidence entries, 3 citations and 1 correction were read locally. Access, acquisition and reading of PubMed gateways, DOI links and original-paper full texts were not attempted. Report-specific historical reading-scope/date fields are absent.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item asks about actual current-action records. Local summaries and unread external material are separated; fields lacking original server metadata remain unrecorded.
Reason for missing information: Current provision/access status of external physical originals has not been verified.
Required materials and conditions: Exact input locations/identity and actual actions for PubMed, DOI and full-text materials
Materials to obtain first: Exact input locations/identity and actual actions for PubMed, DOI and full-text materials
Further research: For permitted new reading, separately record material type, version, success/failure, sections read, original location and identity.
Remaining uncertainty: Current provision/access status of external physical originals has not been verified. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Link local retained-record reading to actual locations; keep external material as not attempted/unread with false flags.
Why this condition is needed: This prevents an external link or historical verification wording from becoming current full-text reading.
Application exceptions: External access not attempted is not access failure. Satisfying this recording criterion is separate from satisfying clinical-material requirements.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03

N33 · Is the remaining scope of external original-table, method and registration comparison stated?

Current findings: Selected epinephrine values, specimen conditions, denominators and original-plan comparisons remain unverified in the retained material. Local item-specific condition/observation review was completed, but no new comparison with external original tables, methods or registration was performed.
Verification status: Met
Materials actually read: The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.
Why unverified: This item evaluates only the statement of remaining comparison scope. Retained locations and unperformed external comparisons are distinguished; actual material requirements in preceding items remain unverified.
Reason for missing information: This is not original-clinical-paper certification, execution of official methods or a latest search.
Required materials and conditions: epinephrine original result tables, methods/appendices, actual registration/SAP identity and currently uncompared locations
Materials to obtain first: epinephrine original result tables, methods/appendices, actual registration/SAP identity and currently uncompared locations
Further research: If new external comparison is authorized, distinguish material acquisition from analysis methods and update each item according to actual results.
Remaining uncertainty: This is not original-clinical-paper certification, execution of official methods or a latest search. No new values, denominators, CI, P or grade calculations/reassessment.
Conditions for verification: Distinguish retained locations actually read from unread external original tables/methods/registration.
Why this condition is needed: This prevents retained-record self-review from being read as original-paper/official-method execution or independent clinical certification.
Application exceptions: This recording criterion states current review scope. Unperformed review is not promoted to a verified clinical comparison or safety.
Referenced methods: Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.

Related sources S01 S02 S03